NovoCure Limited
NVCRNASDAQHealthcareMedical Devices

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Company Information

CEOFrank Leonard
Founded2000
IPO DateOctober 2, 2015
Employees1,488
CountrySwitzerland
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Address
Neuhofstrasse 21 Baar, 6340 Switzerland

Corporate Identifiers

CIK0001645113
CUSIPG6674U108
ISINJE00BYSS4X48
SIC3841

Leadership Team & Key Executives

Frank Leonard
Chief Executive Officer
William F. Doyle
Executive Chairman
Barak Ben-Arye
General Counsel
Dr. Uri Weinberg M.D., Ph.D.
Chief Innovation Officer
Christoph Brackmann
Chief Financial Officer
Mukund Paravasthu
Chief Operating Officer
Ingrid Goldberg
Vice President of Investor Relations
Michael Puri
Chief Human Resources Officer
Dr. Nicolas Leupin M.B.A., M.D., Ph.D.
Chief Medical Officer